CA2756247C

CA2756247C - Method for improved single cell cloning

Info

Publication number: CA2756247C
Application number: CA2756247A
Authority: CA
Inventors: Kolja Hegel; Olaf Krueger; Aziz Cayli
Original assignee: Cellca GmbH
Current assignee: Sartorius Stedim Cellca GmbH
Priority date: 2009-04-09
Filing date: 2010-04-09
Publication date: 2015-05-26
Anticipated expiration: 2030-04-09
Also published as: CN102405279A; WO2010115634A1; KR20110138269A; US20120021510A1; IL215602A; EP2417248B1; WO2010115634A8; CA2756247A1; JP2012523222A; IL215602A0; EP2417248A1; JP5710588B2; KR101617849B1; HUE045635T2; CN102405279B; US8597943B2

Abstract

The present invention relates to methods for the cultivation of a population of cells in a serum free cell culture medium, wherein the population of cells has a cell concentration of less than 100 cells/ml, wherein a serum free cell culture medium containing recombinant albumin and recombinant transferrin is used.

Description

:A 02756247 2011-09-22 Method for improved single cell cloning The present invention relates to methods for the cultivation of a population of cells in a serum free cell culture medium, wherein the population of cells has a cell concentration of less than 100 cells/ml, wherein a serum free cell culture medium containing recombinant albumin and recombinant transferrin is used. The present invention also relates to the use of a serum free cell culture medium containing recombinant albumin and recombinant transferrin for the cultivation of a population of cells with a cell concentration of less than 100 cells/ml. The present invention relates also to a cell population with a cell concentration of less than 100 cells/ml cultivated in a serum free cell culture medium containing recombinant albumin and recombi-nant transferrin. Typical cell culture media are often supplemented with undefined additives, like fetal bovine serum (FBS). Such addi-tives provide carriers for labile or water insoluble components, pro-vide growth factors, and protect cells from physical stress. The use of serum has on the other hand several drawbacks. Serum is an un-characterised mixture of substances which may vary from lot to lot.
However, the main disadvantage of serum or other supplements from animal or human origin is the risk of contamination with adventi-tious agents, e.g. mycoplasma, prions and viruses.
To overcome the pathogenic contamination risk associated with se-rum, serum free media have been developed in the past. Serum free media are often supplemented with serum substitutes, such as growth factors, cytokines, albumin, insulin and transferrin. These pro-teins are generally isolated from an animal source, so that the poten-tial risk of contamination of media with pathogens still exists. For ex-:A 02756247 2011-09-22 ample, cell culture could be facilitated using bovine serum albumin (BSA), human serum albumin (HSA) or transferrin isolated from an animal or human source (US6733746). This approach still runs the risk of introducing adventitious pathogens into the cell culture, such as HIV, Creutzfeld Jakob agent or hepatitis viruses from HSA. The pathogens impact negatively the application of culture media in the production of animal and human therapeutics. Culture media have been described which only contain recombinantly produced proteins and thus reduce the risk of pathogenic contaminations. There are published media containing recombinant albumin together with addi-tional animal drived components (W02008009642) and culture me-dia containing recombinant albumin and recombinant insulin (US20060115901).
A common supplement that is routinely added to serum free media is transferrin. Transferrin is usually isolated from animal or human sources and is added into the serum free culture media to supply cells with iron. Mechanisms of iron uptake by mammalian cells have been reviewed by Qian, Z.M. and Tang, P.L., 1995, Biochim. Bio-phys. Acta, 1269: 205-214. Further publications exist indicating that transferrin might be a growth factor supporting cell proliferation. On the other hand it has been shown that transferrin-receptor deficient cells can proliferate at rates comparable to wild type cell, indicating that this receptor does not belong to the family of growth factor re-ceptors (Chan, R. et. al., 1992, Experimental cell research 202: 326-336). In case of transferrin-receptor deficiency, cells can take up iron through a non-specific receptor-independent mechanism. Generally, there are three mechanisms by which cells can take up iron: 1. from transferrin through a receptor-dependent pathway, 2. from transferrin through a receptor-independent pathway (non-specific), 3. from inor-:A 02756247 2011-09-22 ganic iron salts, e.g. FeSO4 (Chan, R. et. al., 1992, Experimental cell research 202: 326-336). The later way of iron uptake is the back-ground of many inorganic iron chelates added into the culture media, supplying cells with iron and neglecting the other effects of transfer-rin (EP1210410). Due to the non-specific iron uptake of cells from inorganic iron salts, many cell culture media have been developed completely free of any proteins. Interestingly, cells grow in protein free media very well, so that today state of the art culture media are free of any proteins. In summary, the published data demonstrates that transferrin is able to mediate iron uptake in mammalian cells.
However, because cells can take up iron also from inorganic iron chelates, transferrin is not necessarily required for iron supplement.
Up to date, it is not clear if transferrin, besides its assignment as iron provider, has further growth-factor-like effects on cells.
During production of therapeutic proteins with animal cell cultures, it is important to demonstrate the clonality of the production cell line.
This means, that genetically modified production cell lines should originate from a single precursor cell which has been single cell cloned by seeding only one cell per well in a culture dish. Cells in single cell status are exposed to rapidly changing environmental conditions, like pH changes, temperature changes, or deleterious effects of accumulated oxidative media products. In contrast, a cell co-cultured in a cell population receives proliferation and survival supporting components like cytokines from its neighbouring cells.
When this support is omitted during single cell cultivation, many clones cannot survive the elevated culture stress. When a single clone is seeded into a culture dish, like a 96-well plate, the clone does not receive stimulating support from neighbours. This often re-sults in cell death or non-proliferative behaviour. To circumvent these :A 02756247 2011-09-22 difficulties, it is common that single cell cloning is performed in the presence of fetal bovine serum (FBS) in the culture medium. Hence, it is of great interest to develop a serum free single cell cloning me-dium, due to above mentioned disadvantages of serum.
A method has been developed for culturing CHO cells at very low cell densities in a serum free medium. Among others, the medium contains recombinant albumin and recombinant insulin (US20060115901). It is common that conditioned media are added in serum free single cell cloning media. Conditioned media contain cytokines produced by the same cell population and therefore should promote the clonal growth of a single cell (W02005014799). How-ever, the concentration of the cytokines in conditioned media is low and conditioned media contain also growth inhibiting cellular toxic metabolites so that the growth promoting effects of such media are limited.
Another method is the co-culturing of the actual production clone with parental cells. The so-called feeder cells can be radiated in or-der to deprive the cells of the ability to grow. The non-growing feeder cells would release growth factors stimulating the production clone for division (EP1176194, US2005/0059146). The drawback of cul-tures utilizing feeder cells is the difficulty to separate the production clone from the feeder cells. It has to be demonstrated that the feeder cells are not attached to the production clone.
In summary, published data demonstrates that there is a need for new and simple methods for single cell cloning of cells in serum free media.

:A 02756247 2011-09-22 The technical problem underlying the present invention is to provide methods and cell culture media to overcome the disadvantages of the state of the art.
A further technical problem underlying the present invention is to provide a more, simple method for single cell cloning of cells, espe-cially in serum free media.
A further technical problem underlying the present invention is to provide a more simple method for the cultivation of populations of cells with low cell concentration in media, especially in serum free media.
The present invention solves the above-identified problem by the provision of the teaching of the independent claims.
In particular, the present invention provides a method for the cultiva-tion of a population of cells in a serum free cell culture medium, wherein the population of cells has a cell concentration of less than 100 cells/ml, comprising the steps a) culturing a population of cells at a cell concentration greater than about 100 cells/ml, especially greater than 100 cells/ml, in a first serum free cell culture medium, b) reducing the cell concentration to less than about 100 cells/ml, espe-cially to less than 100 cells/ml, and c) culturing the cells in a second serum free cell culture medium, wherein the second serum free cell culture medium contains recombinant albumin and recombinant transferrin.
In particular, the present invention provides a method for the cultiva-tion of a population of cells in a serum free cell culture medium, wherein the population of cells has a cell concentration of less than :A 02756247 2011-09-22 100 cells/ml, comprising the steps a) culturing a population of cells at a cell concentration greater than about 100 cells/ml, especially greater than 100 cells/ml, in a first serum free cell culture medium, b) reducing the cell concentration to less than about 100 cells/ml, espe-dally to less than 100 cells/ml, and c) contacting the cells with a sec-ond serum free cell culture medium, wherein the second serum free cell culture medium contains recombinant albumin and recombinant transferrin.
In a preferred embodiment of the invention the cell concentration in step a) is greater than 200 cells. In a preferred embodiment of the invention the cell concentration in step a) is greater than about 200 cells. In a preferred embodiment of the invention the cell concentra-tion in step a) is greater than 500 cells. In a preferred *embodiment of the invention the cell concentration in step a) is greater than about 1000 cells. In a preferred embodiment of the invention the cell con-centration in step a) is greater than 1000 cells. In a preferred em-bodiment of the invention the cell concentration is reduced in step b) to less than 50 cells/ml. In a preferred embodiment of the invention the cell concentration is reduced in step b) to less than 10 cells/ml. In a preferred embodiment of the invention the cell concentration is re-duced in step b) to 1 cell/ml.
In a preferred embodiment of the invention the cell population is re-duced in step b) to 1 cell. Accordingly, in a preferred embodiment of the invention the cell population contains at the beginning of step c) 1 cell.
In a preferred embodiment of the invention the cell population is re-duced in step b) to 1 cell per culture dish. Accordingly, in a preferred :A 02756247 2011-09-22 embodiment of the invention the cell population contains at the be-ginning of step c) 1 cell per culture dish.
In a preferred embodiment of the invention the cell population is re-duced in step b) to 1 cell per culture well. Accordingly, in a preferred embodiment of the invention the cell population contains at the be-ginning of step c) 1 cell per culture well. A person skilled in the art knows several culture dishes and culture wells which are suitable to culture cells, especially to culture a cell population. A person skilled in the art knows also several culture dishes and culture wells which are suitable to culture a cell population having a cell concentration of less than 100 cells/ml. A person skilled in the art knows also several culture dishes and culture wells which are suitable to culture a cell population having a cell concentration of less than 100 cells in total, especially a cell population consisting of only one single cell.
Furthermore, the present invention provides a method for the cultiva-tion of a single cell in a serum free cell culture medium, comprising the steps a) culturing a population of cells at a cell concentration greater than about 100 cells/ml, especially greater than 100 cells/ml, in a first serum free cell culture medium, b) isolating a single cell out of the population of cells, and c) culturing the single cell in a second serum free cell culture medium, wherein the second cell culture me-dium contains recombinant albumin and recombinant transferrin.
Furthermore, the present invention provides a method for the cultiva-tion of a single cell in a serum free cell culture medium, comprising the steps a) culturing a population of cells at a cell concentration greater than about 103 cells/ml, especially greater than 103 cells/ml, in a first serum free cell culture medium, b) isolating a single cell out :A 02756247 2011-09-22 of the population of cells, and c) contacting the single cell with a sec-ond serum free cell culture medium, wherein the second cell culture medium contains recombinant albumin and recombinant transferrin.
In a preferred embodiment of the invention the cell concentration in step a) is greater than 100 cells. In a preferred embodiment of the invention the cell concentration in step a) is greater than about 200 cells. In a preferred embodiment of the invention the cell concentra-tion in step a) is greater than 500 cells. In a preferred embodiment of the invention the cell concentration in step a) is greater than about 1000 cells. In a preferred embodiment of the invention the cell con-centration in step a) is greater than 10000 cells. In a preferred em-bodiment of the invention the cell concentration in step a) is greater than about 100000 cells. In a preferred embodiment of the invention the cell concentration in step a) is greater than 1000000 cells.
In a preferred embodiment of the invention the cell concentration in step a) is greater than 100 cells/ml. In a preferred embodiment of the invention the cell concentration in step a) is greater than about 200 cells/ml. In a preferred embodiment of the invention the cell concen-tration in step a) is greater than 500 cells/ml. In a preferred embodi-ment of the invention the cell concentration in step a) is greater than about 1000 cells/ml. In a preferred embodiment of the invention the cell concentration in step a) is greater than 10000 cells/ml. In a pre-ferred embodiment of the invention the cell concentration in step a) is greater than about 100000 cells/ml. In a preferred embodiment of the invention the cell concentration in step a) is greater than 1000000 cells/mi.

:A 02756247 2011-09-22 In a preferred embodiment of the invention the cells of the population of cells do not require recombinant transferrin and/or recombinant albumin for growth, when the cells are cultured at a cell concentra-tion greater than about 100 cells/ml. In a preferred embodiment of the invention the cells of the population of cells do not require re-combinant transferrin and/or recombinant albumin for growth, when the cells are cultured at a cell concentration greater than 100 cells/ml. In a preferred embodiment of the invention the cells of the population of cells do not require recombinant transferrin and/or re-to combinant albumin for growth, when the cells are cultured at a cell concentration greater than about 200 cells/ml. In a preferred em-bodiment of the invention the cells of the population of cells do not require recombinant transferrin and/or recombinant albumin for growth, when the cells are cultured at a cell concentration greater than 200 cells/ml. In a preferred embodiment of the invention the cells of the population of cells do not require recombinant transferrin and/or recombinant albumin for growth, when the cells are cultured at a cell concentration greater than about 500 cells/ml. In a preferred embodiment of the invention the cells of the population of cells do not require recombinant transferrin and/or recombinant albumin for growth, when the cells are cultured at a cell concentration greater than 500 cells/ml. In a preferred embodiment of the invention the cells of the population of cells do not require recombinant transferrin and/or recombinant albumin for growth, when the cells are cultured at a cell concentration greater than about 103 cells/ml. In a preferred embodiment of the invention the cells of the population of cells do not require recombinant transferrin and/or recombinant albumin for growth, when the cells are cultured at a cell concentration greater than 103 cells/ml. In a preferred embodiment of the invention the :A 02756247 2011-09-22 cells of the population of cells do not require recombinant transferrin and/or recombinant albumin for growth, when the cells are cultured at a cell concentration greater than about 104 cells/ml. In a preferred embodiment of the invention the cells of the population of cells do not require recombinant transferrin and/or recombinant albumin for growth, when the cells are cultured at a cell concentration greater than 105 cells/ml. In a preferred embodiment of the invention the cells of the population of cells do not require recombinant transferrin andior recombinant albumin for growth, when the cells are cultured at a cell concentration greater than about 106 cells/ml.
In a preferred embodiment of the invention the cells of the population of cells do not require recombinant transferrin for growth, when the cells are cultured at a cell concentration greater than about 100 cells/ml. In a preferred embodiment of the invention the cells of the population of cells do not require recombinant albumin for growth, when the cells are cultured at a cell concentration greater than about 100 cells/ml. In a preferred embodiment of the invention the cells of the population of cells do not require recombinant transferrin for growth, when the cells are cultured at a cell concentration greater than 100 cells/ml. In a preferred embodiment of the invention the cells of the population of cells do not require recombinant albumin for growth, when the cells are cultured at a cell concentration greater than 100 cells/ml. In a preferred embodiment of the invention the cells of the population of cells do not require recombinant transferrin for growth, when the cells are cultured at a cell concentration greater than about 1000 cells/ml. In a preferred embodiment of the invention the cells of the population of cells do not require recombinant albu-min for growth, when the cells are cultured at a cell concentration greater than about 1000 cells/ml. In a preferred embodiment of the :A 02756247 2011-09-22 invention the cells of the population of cells do not require recombi-nant transferrin for growth, when the cells are cultured at a cell con-centration greater than 1000 cells/ml. In a preferred embodiment of the invention the cells of the population of cells do not require re-combinant albumin for growth, when the cells are cultured at a cell concentration greater than 1000 cells/ml.
In a preferred embodiment of the invention the cells of the population of cells are cells which are able to grow in serum free medium. a pre-ferred embodiment of the invention the cells of the population of cells are cells which are adapted to grow in an serum free medium.
In a preferred embodiment of the invention the cells of the population of cells are cells which are able to grow in animal component free medium. In a preferred embodiment of the invention the cells of the population of cells are cells which are adapted to grow in an animal component free medium. In a preferred embodiment of the invention the cells of the population of cells are cells which are able to grow in animal component free medium in a concentration of less than 100 cells/ml. In a preferred embodiment of the invention the cells of the population of cells are cells which are adapted to grow in an animal component free medium in a concentration of less than 100 cells/ml.
In a preferred embodiment of the invention the method comprises an additional step before step a) wherein the cells of the population of cells are adapted to grow in an animal component free medium. In an alternative embodiment of the invention the cells of the population of cells are adapted to grow in an animal component free medium in step a).

:A 02756247 2011-09-22 The cells which are adapted to grow in an animal component free medium can also be provided, e.g. by using commercially available cells, to be used in step a).
Suitable methods to adapt cells to grow in an animal component free medium, i.e. to obtain cells which are adapted to grow in an animal component free medium are well known in the state of the art.
In a preferred embodiment of the invention the animal component free medium is a protein free medium.
In a preferred embodiment of the invention the first serum free me-dium used in step a) contains albumin in a concentration of less than 0,1 % per weight. In a preferred embodiment of the invention the first serum free medium used in step a) contains albumin in a concentra-tion of at most 0,09 % per weight. In a preferred embodiment of the invention the first serum free medium used in step a) contains albu-min in a concentration of at most 0,05 % per weight. In a preferred embodiment of the invention the first serum free medium used in step a) contains albumin in a concentration of at most 0,01 % per weight.
In a preferred embodiment of the invention the first serum free me-dium used in step a) contains recombinant albumin in a concentra-tion of less than 0,1 % per weight. In a preferred embodiment of the invention the first serum free medium used in step a) contains re-combinant albumin in a concentration of at most 0,09 % per weight.
In a preferred embodiment of the invention the first serum free me-dium used in step a) contains recombinant albumin in a concentra-tion of at most 0,05 A per weight. In a preferred embodiment of the :A 02756247 2011-09-22 invention the first serum free medium used in step a) contains re-combinant albumin in a concentration of at most 0,01 % per weight.
In a preferred embodiment of the invention the first serum free me-dium used in step a) contains transferrin in a concentration of less than 5 pg/ml. In a preferred embodiment of the invention the first se-rum free medium used in step a) contains transferrin in a concentra-tion of at most 4,9 pg/ml. In a preferred embodiment of the invention the first serum free medium used in step a) contains transferrin in a concentration of at most 4 pg/ml. In a preferred embodiment of the invention the first serum free medium used in step a) contains trans-ferrin in a concentration of at most 1 pg/ml. In a preferred embodi-ment of the invention the first serum free medium used in step a) contains transferrin in a concentration of at most 0,5 pg/ml.
In a preferred embodiment of the invention the first serum free me-dium used in step a) contains recombinant transferrin in a concentra-tion of less than 5 pg/ml. In a preferred embodiment of the invention the first serum free medium used in step a) contains recombinant transferrin in a concentration of at most 4,9 pg/ml. In a preferred em-bodiment of the invention the first serum free medium used in step a) contains recombinant transferrin in a concentration of at most 4 pg/ml. In a preferred embodiment of the invention the first serum free medium used in step a) contains recombinant transferrin in a con-centration of at most 1 pg/ml. In a preferred embodiment of the in-vention the first serum free medium used in step a) contains recom-binant transferrin in a concentration of at most 0,5 pg/ml.
In a preferred embodiment of the invention the first serum free me-dium used in step a) contains no recombinant albumin. In a preferred :A 02756247 2011-09-22 embodiment of the invention the first serum free medium used in step a) contains no recombinant transferrin. In a preferred embodi-ment of the invention the first serum free medium used in step a) contains no recombinant albumin and no recombinant transferrin.
In a preferred embodiment of the invention the first serum free me-dium used in step a) contains no albumin and no transferrin.
In a preferred embodiment of the invention the cell culture medium used in step c) contains more than 2 g/I recombinant albumin. In a preferred embodiment of the invention the cell culture medium used in step c) contains at least 2,1 g/I recombinant albumin. In a pre-ferred embodiment of the invention the cell culture medium used in step c) contains at least 2,5 g/I recombinant albumin. In a preferred embodiment of the invention the cell culture medium used in step c) contains at least 3 g/I recombinant albumin. In a preferred embodi-ment of the invention the cell culture medium used in step c) con-tains at least 5 g/I recombinant albumin. In a preferred embodiment of the invention the cell culture medium used in step c) contains at least 10 g/I recombinant albumin. In a preferred embodiment of the invention the cell culture mediuM used in step c) contains at least 20 g/I recombinant albumin.
In a preferred embodiment of the invention the cell culture medium used in step c) contains more than 10 mg/I recombinant transferrin.
In a preferred embodiment of the invention the cell culture medium used in step c) contains at least 10, 1 mg/I recombinant transferrin.
In a preferred embodiment of the invention the cell culture medium used in step c) contains at least 11 mg/I recombinant transferrin. In a preferred embodiment of the invention the cell culture medium used :A 02756247 2011-09-22 in step c) contains at least 20 mg/I recombinant transferrin. In a pre-ferred embodiment of the invention the cell culture medium used in step c) contains at least 50 mg/I recombinant transferrin. In a pre-ferred embodiment of the invention the cell culture medium used in step c) contains at least 100 mg/I recombinant transferrin.
In a preferred embodiment of the invention the cell culture medium used in step a) contains less than 2 g/I recombinant albumin and wherein the cell culture medium used in step c) contains more than 2 g/I recombinant albumin, In a preferred embodiment of the invention the cell culture medium used in step a) contains less than 1 g/I re-combinant albumin and wherein the cell culture medium used in step c) contains more than 1 g/I recombinant albumin. In a preferred em-bodiment of the invention the cell culture medium used in step a) contains less than 2 g/I recombinant albumin and wherein the cell culture medium used in step c) contains more than 1 g/I recombinant albumin. In a preferred embodiment of the invention the cell culture medium used in step a) contains less than 1 9/1 recombinant albumin and wherein the cell culture medium used in step c) contains more than 2 g/I recombinant albumin. In a preferred embodiment of the invention the cell culture medium used in step a) contains at most 0,5 g/I recombinant albumin and wherein the cell culture medium used in step c) contains at least than 215 g/I recombinant albumin.
In a preferred embodiment of the invention the cell culture medium used in step a) contains less than 5 pg/ml recombinant transferrin and wherein the cell culture medium used in step c) contains more than 5 pg/ml recombinant transferrin. In a preferred embodiment of the invention the cell culture medium used in step a) contains less than 10 pg/ml recombinant transferrin and wherein the cell culture :A 02756247 2011-09-22 medium used in step c) contains more than 10 pg/ml recombinant transferrin. In a preferred embodiment of the invention the cell cul-ture medium used in step a) contains less than 5 pg/ml recombinant transferrin and wherein the cell culture medium used in step c) con-tains more than 10 pg/ml recombinant transferrin. In a preferred em-bodiment of the invention the cell culture medium used in step a) contains less than 10 pg/ml recombinant transferrin and wherein the cell culture medium used in step c) contains more than 5 pg/ml re-( combinant transferrin. In a preferred embodiment of the invention the cell culture medium used in step a) contains at most 4 pg/ml recom-binant transferrin and wherein the cell culture medium used in step c) contains at least 6 pg/ml recombinant transferrin.
In a preferred embodiment of the invention the cell culture medium used in step a) contains less than 2 g/I recombinant albumin and less than 5 pg/ml recombinant transferrin and the cell culture medium used in step c) contains more than 2 g/I recombinant albumin more than 5 pg/ml recombinant transferrin. In a preferred embodiment of the invention the cell culture medium used in step a) contains less than 1 g/I recombinant albumin and less than 10 pg/ml recombinant transferrin and wherein the cell culture medium used in step c) con-tains more than 1 g/I recombinant albumin more than 10 pg/ml re-combinant transferrin. In a preferred embodiment of the invention the cell culture medium used in step a) contains less than 1 g/I recombi-nant albumin and less than 5 pg/ml recombinant transferrin and the cell culture medium used in step c) contains more than 2 g/I recom-binant albumin more than 10 pg/ml recombinant transferrin. In a pre-ferred embodiment of the invention the cell culture medium used in step a) contains at most 0,5 g/I recombinant albumin and at most 4 pg/ml recombinant transferrin and the cell culture medium used in :A 02756247 2011-09-22 step c) contains at least 3 g/I recombinant albumin at least 15 ug/m1 recombinant transferrin.
In a preferred embodiment of the invention the cell culture medium used in step a) contains less recombinant albumin, especially albu-min, than the cell culture medium used in step c). In a preferred em-bodiment of the invention the cell culture medium used in step a) contains less recombinant transferrin, especially transferrin, than the cell culture medium used in step c). In a preferred embodiment of the invention the cell culture medium used in step a) contains less re-combinant albumin, especially albumin, and less recombinant trans-ferrin, especially transferrin, than the cell culture medium used in step c).
In a preferred embodiment of the invention the cell culture medium used in step a) is an animal component free medium, more prefera-bly a protein free medium. In a preferred embodiment of the inven-tion the cell culture medium used in step c) is an animal component free medium.
In a preferred embodiment of the invention, the method comprises additionally the step d) culturing the cells in a third serum free cell culture medium which has a lower concentration of recombinant transferrin and/or recombinant albumin than the cell culture medium of step c). In a preferred embodiment of the invention, the method comprises additionally the step d) culturing the cells in a third serum free cell culture medium which has a lower concentration of recom-binant transferrin and recombinant albumin than the cell culture me-dium of step c). In a preferred embodiment of the invention, the method comprises additionally the step d) culturing the cells in a third :A 02756247 2011-09-22 serum free cell culture medium which has a lower concentration of recombinant transferrin than the cell culture medium of step c). In a preferred embodiment of the invention, the method comprises addi-tionally the step d) culturing the cells in a third serum free cell culture medium which has a lower concentration of recombinant albumin than the cell culture medium of step c).
In a preferred embodiment of the invention, the method comprises additionally the step d) culturing the cells in a third serum free cell culture medium which has concentration of recombinant transferrin and of recombinant albumin which is 80% or lower, preferably 50 %
or lower, than the concentration of recombinant transferrin and of recombinant albumin in the cell culture medium of step c).
In a preferred embodiment of the invention, the method comprises additionally the step d) culturing the cells in a third serum free cell culture medium which has an at least two-fold lower concentration of recombinant transferrin and an at least two-fold lower concentration of recombinant albumin than the cell culture medium of step c).
C. According to the preferred embodiment the step d) follows step c).
In a preferred embodiment of the invention the cell culture medium of step d) is free of recombinant transferrin and recombinant albumin.
In a preferred embodiment of the invention the serum free cell cul-ture medium is an animal component free cell culture medium. In a preferred embodiment of the invention the serum free cell culture medium is a protein free cell culture medium.

:A 02756247 2011-09-22 In a preferred embodiment of the invention the serum free cell cul-ture medium of step a) is an animal component free cell culture me-dium. In a preferred embodiment of the invention the serum free cell culture medium of step a) is a protein free cell culture medium.
In a preferred embodiment of the invention the serum free cell cul-ture medium of step c) is an animal component free cell culture me-dium. In a preferred embodiment of the invention the serum free cell =
culture medium of step c) is a protein free cell culture medium.
In a preferred embodiment of the invention the serum free cell cul-l() ture medium of step d) is an animal component free cell culture me-dium. In a preferred embodiment of the invention the serum free cell culture medium of step d) is a protein free cell culture medium.
In a preferred embodiment of the invention the cell culture medium of step c) has an osmolality between 280 and 320 mOsmol/kg H20.
In a preferred embodiment of the invention the cell culture medium of step c) has an osmolality between 280 and 300 mOsmol/kg H20.In a preferred embodiment of the invention the cell culture medium of step c) has a pH between 6.0 and 8Ø In a preferred embodiment of the invention the cell culture medium of step c) has a pH between 6.8 and 7.1.
In a preferred embodiment of the invention the cell culture medium of step c) has an osmolality between 280 and 320 mOsmol/kg H20 and a pH between 6.8 and 7.1.
In a preferred embodiment of the invention the cell culture medium of step c) has an osmolality between 280 and 300 mOsmol/kg H20 and :A 02756247 2011-09-22 a pH between 6.8 and 7ØIn a preferred embodiment of the inven-tion the cell culture medium used in step a) and/or c), and/or d) con-tains L-glutamine. In a preferred embodiment of the invention the cell culture medium used in step a) and/or c), and/or d) contains L-glutamine in a concentration lower than 6 mM. In a preferred em-bodiment of the invention the cell culture medium used in step a) and/or c), and/or d) contains L-glutamine in a concentration lower than 4 mM, In a preferred embodiment of the invention the cell cud-( ture medium used in step a) and/or c), and/or d) contains L-glutamine in a concentration lower than 2 mM. In a preferred em-bodiment of the invention the cell culture medium used in step a) and/or c), and or d) does not contain L-glutamine.
In a preferred embodiment of the invention the cell culture medium contains L-glutamine. In a preferred embodiment of the invention the cell culture medium used in step c) contains L-glutamine. In a pre-ferred embodiment of the invention the cell culture medium used in step d) contains L-glutamine. In a preferred embodiment of the in-vention the cell culture media used in steps a) and c) contain L-, glutamine. In a preferred embodiment of the invention the cell culture media used in steps a), c) and d) contain L-glutamine.
In a preferred embodiment of the invention the cell culture medium used in step a) contains L-glutamine in a concentration lower than 50 mM. In a preferred embodiment of the invention the cell culture me-dium used in step c) contains L-glutamine in a concentration lower than 50 mM. In a preferred embodiment of the invention the cell cul-ture medium used in step d) contains L-glutamine in a concentration lower than 50 mM.

:A 02756247 2011-09-22 In a preferred embodiment of the invention the cell culture medium used in step a) contains L-glutamine in a concentration lower than 6 mM. In a preferred embodiment of the invention the cell culture me-dium used in step c) contains L-glutamine in a concentration lower than 6 mM. In a preferred embodiment of the invention the cell cul-ture medium used in step d) contains L-glutamine in a concentration lower than 6 mM.
In a preferred embodiment of the invention the cell culture medium used in step a) contains L-glutamine in a concentration lower than 4 mM. In a preferred embodiment of the invention the cell culture me-dium used in step c) contains L-glutamine in a concentration lower than 4 mM. In a preferred embodiment of the invention the cell cul-ture medium used in step d) contains L-glutamine in a concentration lower than 4 mM.
In a preferred embodiment of the invention the cell culture media used in steps a) and c) contain L-glutamine in a concentration lower than 50 mM. In a preferred embodiment of the invention the cell cul-ture media used in steps a) and c) contain L-glutamine in a concen-tration lower than 6 mM. In a preferred embodiment of the invention the cell culture media used in steps a) and c) contain L-glutamine in a concentration lower than 4 mM. In a preferred embodiment of the invention the cell culture media used in steps a), c) and d) contain L-glutamine in a concentration lower than 4 mM.
In a preferred embodiment of the invention all cell culture media used contain L-glutamine in the same concentration. In a preferred embodiment of the invention all cell culture media used contain L-glutamine in a concentration of lower than 50 mM. In a preferred :A 02756247 2011-09-22 embodiment of the invention all cell culture media used contain L-glutamine in a concentration of lower than 20 mM. In a preferred embodiment of the invention all cell culture media used contain L-glutamine in a concentration of lower than 6 mM. In a preferred em-bodiment of the invention all cell culture media used contain L-glutamine in a concentration of lower than 4 mM. In a preferred em-bodiment of the invention the cell culture media used in steps a) and/or c) contain iron. In a preferred embodiment of the invention the cell culture media used in steps a) and/or c) and/or d) contain iron.
In a preferred embodiment of the invention the cell culture medium used in step a) contains iron. In a preferred embodiment of the in-vention the cell culture medium used in step c) contains iron. In a preferred embodiment of the invention the cell culture medium used in step d) contains iron. In a preferred embodiment of the invention the cell culture media used in steps a) and c) contain iron.
In a preferred embodiment of the invention the cell culture medium used in step a) contains a non-transferrin bound iron. In a preferred embodiment of the invention the cell culture medium used in step c) ( contains a non-transferrin bound iron. In a preferred embodiment of the invention the cell culture medium used in step d) contains a non-transferrin bound iron.
In a preferred embodiment of the invention the cell culture media used in steps a) and/or c) contain a non-transferrin bound iron. In a preferred embodiment of the invention the cell culture media used in steps a) and/or c) and/or d) contain a non-transferrin bound iron.
In a preferred embodiment of the invention the cell culture media used in steps a) and c) contain a non-transferrin bound iron. In a pre-:A 02756247 2011-09-22 ferred embodiment of the invention the cell culture media used in steps a), c) and d) contain a non-transferrin bound iron.
In a preferred embodiment of the invention the cells are cultured in step a) for at least 1 day without sub-culturing the cells. In a pre-ferred embodiment of the invention the cells are cultured in step a) for at least 2 days without sub-culturing the cells. In a preferred em-bodiment of the invention the cells are cultured in step a) at least 3 days without sub-culturing the cells.
In a preferred embodiment of the invention the cells are cultured in step c) for at least 5 days. In a preferred embodiment of the inven-tion the cells are cultured .in step c) for at least 10 days. In a pre-ferred embodiment of the invention the cells are cultured in step c) for at least 5 days without sub-culturing the cells. In a preferred em-bodiment of the invention the cells are cultured in step c) for at least 10 days without sub-culturing the cells.
In a preferred embodiment of the invention the cells are cultured in step d) for at least 3 days. In a preferred embodiment of the inven-tion the cells are cultured in step d) for at least 6 days.
In a preferred embodiment of the invention the cells are cultured in step d) for at least 3 days without sub-culturing the cells. In a pre-ferred embodiment of the invention the cells are cultured in step d) for at least 6 days without sub-culturing the cells.
In a preferred embodiment of the invention the cells are cultured in steps c) and d) together for at least 3 days. In a preferred embodi-ment of the invention the cells are cultured in steps c) and d) to-gether for at least 6 days.

:A 02756247 2011-09-22 In a preferred embodiment of the invention the cells are cultured in steps c) and d) together for at least 3 days without sub-culturing the cells. In a preferred embodiment of the invention the cells are cul-tured in steps c) and d) together for at least 6 days without sub-culturing the cells.
In a preferred embodiment of the invention the culture volume in step a) is 0.1 ml, more preferred 0.5 ml, more preferred 3 ml, more pre-ferred 15 ml, more preferred 100 ml.
In a preferred embodiment of the invention the culture volume in step a) is at least 0.1 ml. In a preferred embodiment of the invention the culture volume in step a) is at least 0.5 mi. In a preferred embodi-ment of the invention the culture volume in step a) is at least 3 mi. In a preferred embodiment of the invention the culture volume in step a) is about 3 mi. in a preferred embodiment of the invention the cut-ture volume in step a) is at least 15 ml. In a preferred embodiment of the invention the culture volume in step a) is about 15 ml. In a pre-ferred embodiment of the invention the culture volume in step a) is at least 100 mi. In a preferred embodiment of the invention the culture volume in step a) is about 100 ml. In a preferred embodiment of the invention the culture volume in step a) is at most 1 I. In a preferred embodiment of the invention the culture volume in step a) is at most 0,5 1.1n a preferred embodiment of the invention the culture volume in step c) is at most about 5 ml. In a preferred embodiment of the in-vention the culture volume in step c) is at most 2 ml. In a preferred embodiment of the invention the culture volume in step c) is at most about 2 ml. In a preferred embodiment of the invention the culture volume in step c) is at most about 1 ml. In a preferred embodiment of the invention the culture volume in step c) is at most 450 pl. In a pre-:A 02756247 2011-09-22 ferred embodiment of the invention the culture volume in step c) is at most 150 pl. In a preferred embodiment of the invention the culture volume in step c) is at most 100 pl. In a preferred embodiment of the invention the culture volume in step c) is at most about 100 pl. In a preferred embodiment of the invention the culture volume in step c) is 30 pl. In a preferred embodiment of the invention the culture vol-ume in step c) is at most 10 pl. In a preferred embodiment of the in-vention the culture volume in step c) is at most about 10 pl.
In a preferred embodiment of the invention the culture volume in step C) is at least 1 pl. In a preferred embodiment of the invention the cul-ture volume in step c) is at least 5 pl. In a preferred embodiment of the invention the culture volume in step c) is at least about 5 pl. In a preferred embodiment of the invention the culture volume in step c) is at least about 10 pl. In a preferred embodiment of the invention the culture volume in step c) is at least 100 pl. In a preferred em-bodiment of the invention the culture volume in step c) is at least about 100 pl. In a preferred embodiment of the invention the culture volume in step c) is at least about 0,5 ml. In a preferred embodiment of the invention the culture volume in step c) is at least 0,5 mi. In a preferred embodiment of the invention the culture volume in step c) is at least about 1 ml. In a preferred embodiment of the invention the culture volume in step d) is at most 20 pl. In a preferred embodiment of the invention the culture volume in step d) is at most 60 pl. In a preferred embodiment of the invention the culture volume in step d) is at most 200 pl. In a preferred embodiment of the invention the cul-ture volume in step d) is at most 600 pl. In a preferred embodiment of the invention the culture volume in step d) is 1.8 ml. In a preferred embodiment of the invention the culture volume in step d) is at most 5m!.

:A 02756247 2011-09-22 In a preferred embodiment of the invention the culture volume in step d) is at least 1 pl. In a preferred embodiment of the invention the cul-ture volume in step d) is at least about 1 pl. In a preferred embodi-ment of the invention the culture volume in step d) is at least 10 pl. In a preferred embodiment of the invention the culture volume in step d) is at least about 10 pl. In a preferred embodiment of the invention the culture volume in step d) is at least 50 pl. In a preferred embodi-ment of the invention the culture volume in step d) is at least 100 pl.
In a preferred embodiment of the invention the culture volume in step d) is at least 300 pl. In a preferred embodiment of the invention the culture volume in step d) is at least about 1.5 ml. In a preferred em-bodiment of the invention the culture volume in step d) is at least about 3 ml. In a preferred embodiment of the invention the culture volume in step d) is at least 3 ml. In a preferred embodiment of the invention the cell culture medium used in step c) contains at least 50 mg/I recombinant albumin. In a preferred embodiment of the inven-tion the cell culture medium used in step c) contains at least 200 mg/I
recombinant albumin. In a preferred embodiment of the invention the cell culture medium used in step c) contains at least 1000 mg/I re-combinant albumin. In a preferred embodiment of the invention the cell culture medium used in step c) contains at least 2000 mg/I re-combinant albumin. In a preferred embodiment of the invention the cell culture medium used in step c) contains at least 5000 mg/I re-combinant albumin. In a preferred embodiment of the invention the cell culture medium used in step c) contains at most 50000 mg/I re-combinant albumin. In a preferred embodiment of the invention the cell culture medium used in step c) contains at least 0.1 mg/I recom-binant transferrin. In a preferred embodiment of the invention the cell culture medium used in step c) contains at least 1 mg/I recombinant :A 02756247 2011-09-22 transferrin. In a preferred embodiment of the invention the cell cul-ture medium used in step c) contains at least 5 mg/1 recombinant transferrin. In a preferred embodiment of the invention the cell cul-ture medium used in step c) contains at least 50 mg/I recombinant transferrin. In a preferred embodiment of the invention the cell cul-ture medium used in step c) contains at least 250 mg/I recombinant transferrin. In a preferred embodiment of the invention the cell cul-ture medium used in step c) contains at most 2500 mg/I recombinant transferrin. In a preferred embodiment of the invention the cell cul-ture medium used in step c) contains at least 50 mg/I recombinant albumin and at least 0.1 mg/I recombinant transferrin. In a preferred embodiment of the invention the cell culture medium used in step c) contains at least 1000 mg/I recombinant albumin and at least 1 mg/I
recombinant transferrin. In a preferred embodiment of the invention the cell culture medium used in step c) contains at least 2000 mg/I
recombinant albumin and at least 5 mg/I recombinant transferrin. In a preferred embodiment of the invention the cell culture medium used in step c) contains at least 5000 mg/I recombinant albumin and at least 50 mg/I recombinant transferrin.
In a preferred embodiment of the invention the cell culture medium used in step d) contains less than 5000 mg/I recombinant albumin. In a preferred embodiment of the invention the cell culture medium used in step d) contains less than 50 mg/I recombinant transferrin.
In a preferred embodiment of the invention the cell culture medium used in step d) contains less than 5000 mg/I recombinant albumin and less than 50 mg/1 recombinant transferrin. In a preferred em-bodiment of the invention the cell culture medium used in step d) contains less than 2000 mg/I recombinant albumin and less than 5 :A 02756247 2011-09-22 mg/I recombinant transferrin. In a preferred embodiment of the in-vention the cell culture medium used in step d) contains less than 50 mg/I recombinant albumin and less than 0.1 mg/I recombinant trans-.
ferrin. In a preferred embodiment of the invention the cell culture medium used in step d) does not contain recombinant albumin and does not contain recombinant transferrin.
In a preferred embodiment of the invention the cell culture medium used in step a) is an animal component free culture medium. In a ( preferred embodiment of the invention the cell culture medium used in step c) is an animal component free culture medium. In a pre-ferred embodiment of the invention the cell culture medium used in step d) is an animal component free culture medium.
In a preferred embodiment of the invention the cell culture media used in steps a) and c) are animal component free culture media. In a preferred embodiment of the invention the cell culture media used in steps c) and d) are animal component free culture media. In a pre-ferred embodiment of the invention the cell culture media used in steps a), c) and d) are animal component free culture media.
In a preferred embodiment of the invention all cell culture media used are animal component free cell culture media. In a preferred = embodiment of the invention the cell population is reduced in step b) by an automatic cell sorting system.
In a preferred embodiment of the invention the single cell is isolated in step b) by an automatic cell sorting system. In a preferred em-bodiment of the invention the single cell is isolated in step b) by FACS.

:A 02756247 2011-09-22 In a preferred embodiment of the invention the cells of the population of cells contain no feeder cells.
In a preferred embodiment of the invention the cells of the population of cells are eukaryotic cells. In a preferred embodiment of the inven-lion the cells of the population of cells are mammalian cells. In a pre-ferred embodiment of the invention the cells of the population of cells are human cells. In a preferred embodiment of the invention the cells of the population of cells are animal cells. In a preferred embodiment of the invention the cells of the population of cells are not human embryonic stem cells.
In a preferred embodiment of the invention the population of cells is a cell line. In a preferred embodiment of the invention the population of cells is a CHO cell line, a NSO cell line, a Per.C6 cell line, a HEK293 cell line or a BHK cell line. In a preferred embodiment of the invention the population of cells is a CHO cell line. In a preferred embodiment of the invention the population of cells is a cell line. In a preferred embodiment of the invention the population of cells is a NSO cell line. In a preferred embodiment of the invention the popula-tion of cells is a cell line. In a preferred embodiment of the invention the population of cells is a Per.C6 cell line. In a preferred embodi-ment of the invention the population of cells is a cell line. In a pre-ferred embodiment of the invention the population of cells is a HEK293 cell line. In a preferred embodiment of the invention the population of cells is a cell line. In a preferred embodiment of the invention the population of cells is a BHK cell line. In a preferred em-bodiment of the invention the cells of the population of cells are pro-karyotic cells.

:A 02756247 2011-09-22 The present invention relates also in a preferred embodiment to the use of a serum free cell culture medium containing recombinant al-bumin and recombinant transferrin for the cultivation of a population of cells with a cell concentration of less than about 100 cells/ml. The present invention relates also in a preferred embodiment to the use of a serum free cell culture medium containing recombinant albumin and recombinant transferrin for the cultivation of a population of cells with a cell concentration of less than 100 cells/ml.
The present invention relates also in a preferred embodiment to the use of a serum free cell culture medium containing recombinant al-bumin and recombinant transferrin for the cultivation of a single cell.
The preferred embodiments concerning the method according to the present invention are also preferred embodiments for the use ac-cording to the present invention.
The present invention relates also in a preferred embodiment to a cell population with a cell concentration of less than about 100 cells/m1 cultivated in a serum free cell culture medium containing re-combinant albumin and recombinant transferrin.
The present invention relates also in a preferred embodiment to a cell population with a cell concentration of less than 100 cells/ml cul-tivated in a serum free cell culture medium containing recombinant albumin and recombinant transferrin.
The present invention relates also in a preferred embodiment to a single cell cultivated in a serum free cell culture medium containing recombinant albumin and recombinant transferrin. The preferred embodiments concerning the method according to the present inven-:A 02756247 2011-09-22 tion are also preferred embodiments for the cell population in a se-rum free cell culture medium containing recombinant albumin and recombinant transferrin according to the present invention.
The here presented invention is a serum free culture medium for single cell cloning containing recombinant albumin and recombinant transferrin. The experiments were performed with CHO cell lines al-ready adapted to grow in a culture medium free of serum, growth factors, proteins, and peptones. The culture medium contains an inorganic iron source. In this culture media the cell line reaches a cell concentration up to 3x107 cells/ml in a fed-batch process. This dem-onstrates a very good growth independently from serum and protein additives. However, the efficacy of the clonal growth of the same cells in single cell status in the same medium was very low.
Surprisingly we have found that clonal growth of the cell line can be significantly enhanced by addition of recombinant proteins. It turned out that cell lines have different demands on culture media when grown in single cell status as compared to growth in a population of cells. A person skilled in the art would think that a serum and protein independent growing cell line should also clonally grow in a milieu free of serum and proteins. We were surprised to find out, that the same cell line has different requirements on media when cultured in a single cell state and in a cell population.
Accordingly, it is surprisingly only necessary that recombinant albu-min and/or recombinant transferrin is present in step c). The cells do not need recombinant albumin and/or recombinant transferrin before and after step c), at least in high concentrations.

:A 02756247 2011-09-22 According to our invention, a cell line will be contacted with a culture medium containing recombinant albumin and recombinant transfer-rin, when the clonal cell growth is required. Apparently recombinant albumin and recombinant transferrin have a synergistic effect on cells. Both proteins were also tested separately. They promote the cell proliferation each at a low level. When both proteins were com-bined, cell growth and viability of single cells is significantly increased almost at the levels of serum containing control cultures or even higher than serum containing control cultures.
We have further examined if additional parameters of the culture media plays a role in improving the clonal growth. To our surprise we have found, that single cells have different requirements also regard-ing the culture media osmolality and culture media pH. The clonal growth can be even more improved when the osmolality of the cul-ture medium is lowered. Preferred osmolality of the culture medium is between 260 and 360 mOsmol/kg H20, more preferred 270 to 340, more preferred 280 to 320, more preferred 290 to 300 mOsmol/kg H20. The clonal growth can be even more improved when the pH of the culture medium is lower than usual in culture media. Preferred culture medium pH is between 6.7 and 7.3, more preferred 6.8 and 7.2, more preferred 6.8 and 7Ø
Recombinant proteins as media additives are expensive. It is there-fore, interesting omitting the recombinant proteins in culture media.
According to a preferred embodiment of the invention an easy and cost efficient way of promoting the clonal growth is in a first step cul-turing cells in a medium containing low concentration of recombinant albumin and recombinant transferrin or culturing cells in a medium which is free of recombinant albumin and recombinant transferrin. In :A 02756247 2011-09-22 a second step the cells are contacted with a culture medium contain-ing recombinant albumin and recombinant transferrin at higher con-centration than applied in the first step. In step three the cells can be cultured in a culture medium with lower concentration of recombinant albumin and recombinant transferrin or recombinant albumin and recombinant transferrin can be completely omitted. Through this pro-cedure practically, the recombinant albumin and recombinant trans-ferrin can be applied only by reduced cell concentration or in single cell cloning step and in all other cell culturing steps the expensive recombinant proteins can be omitted and a cost efficient and easy method can be established for single cell cloning.
Another main advantage of the method according to the invention is that cells can be cultured through out all steps in animal component free culture media, which has great advantage for regulatory authori-ties by production of therapeutic proteins.
The term "recombinant protein" refers to a protein that is encoded by a nucleic acid that is introduced into a host cell. The host cell ex-presses the nucleic acid. "Protein" as used herein broadly refers to polymerised amino acids, e.g. peptides, polypeptides, protein, lipo-proteins, glycoproteins, etc.
The term "serum free medium" or "serum free cell culture medium" is a medium that contains no serum from any organism (e.g. fetal bo-vine serum (FBS), calf serum, horse serum, goat serum, human se-rum, etc.).
The term "cell culture" or "culture" is meant the maintenance of cells in an artificial, in vitro environment, it is to be understood, however, that the term "cell culture" is a generic term and may be used to en-:A 02756247 2011-09-22 compass the cultivation not only of individual cells or only single cell or only a cell population, but also of tissues or organs, for which the terms "tissue culture" or "organ culture", may occasionally be used interchangeably with the term "cell culture".
The term "contacting" refers to the placing of cells to be cultivated in vitro into a culture vessel with the medium in which the cells are to be cultivated. The term "contacting" encompasses mixing cells with .a medium, pipetting medium onto cells in a culture vessel, and sub-merging cells in a culture medium.
The term "albumin" refers to a protein which is an abundant protein contained in plasma. It contributes to the maintenance of osmotic pressure in blood and probably binds to nutrients to transport these substances to cells. Different versions of albumin exists, for example but not limited to human serum albumin (HSA), bovine serum albu-min (BSA), a fraction or a part of HSA, a fraction or a part of BSA.
Albumin might be further any protein or polypeptide which gives sub-stantially similar results in terms of cell growth, cell viability or cellular productivity regarding osmolality regulation of medium and regarding nutrient binding or nutrient transfer to cells. Preferably the albumin is of human origin. Most preferably the albumin is human serum albu-min. Even more preferably the albumin is recombinantly produced human serum albumin ("recombinant HSA"). The recombinant HSA
can be produced in divers organisms, like prokaryotic or eukaryotic cells, e.g. bacteria, plant or yeast, etc. The production of recombi-nant albumin is known in the art in numerous hosts e.g. E. coli (EP73646) and fungal cell (W00044772). For example but not lim-ited to the recombinant albumin is a human recombinant albumin as stated out by Sigma (A7223).

:A 02756247 2011-09-22 The term "transferrin" refers to any biological compound which has iron binding or chelating abilities. Examples of transferrin include but are not limited to any protein, polypeptide or peptide which has an affinity to iron, for example iron binding or chelating abilities. Other examples of transferrin include but are not limited are proteins, poly-peptides or peptides which have any affinity to cellular transferrin receptor. Such proteins, polypeptides or peptides can recognise, bind partly, or bind fully the cellular transferrin receptor. Transferrin can be saturated with iron or not. If transferrin is not saturated with iron, the culture media might contain inorganic iron. If transferrin is saturated with iron the culture media can be free of inorganic iron or the culture media can contain additionally inorganic iron. Preferably transferrin is saturated with iron. More preferably, transferrin is iron saturated human transferrin.
The term "recombinant transferrin" is the transferrin which is recom-binantly produced in any organism. The recombinant transferrin can be produced in divers organisms, like prokaryotic or eukaryotic cells.
Recombinant transferrin can be produced in bacteria, plant, fungi or yeast. Preferred is the recombinantly produced human transferrin.
For example but not limited to recombinant human transferrin is the recombinant human transferrin from Millipore (9701-10) as described in the product specification.
The present invention relates in a particularly preferred embodiment to a culture medium, wherein the recombinant albumin is contained therein in a concentration of at least, preferably more than 0.1 g/I, at least preferably more than 0.2 g/I, at least preferably more than 0.5 g/I, at least preferably more than 1.0 g/I, at least preferably more than 2 g/l, or in a particularly preferred embodiment at least prefera-:A 02756247 2011-09-22 bly more than 3 g/I, or in a further particularly preferred embodiment at least preferably more than 5 g/I. In a further preferred embodi-ment, the present invention provides a culture medium according to the above, wherein the concentration of the recombinant transferrin is at least, preferably more than 0.1 mg/I, at least preferably more than 1 mg/I, at least preferably more than 2 mg/I, at least preferably more than 4 mg/I, at least preferably more than 6 mg/I, at least pref-erably more than 8 mg/I, at least preferably more than 10 mg/I, at least preferably more than 20 mg/I, at least preferably more than 50 mg/I, at least preferably more than 200 mg/I, or in a particularly pre-ferred embodiment at least, preferably more than, 1000 mg/I.
The term "animal component free" refers to a culture medium or to a cell culture process, in which no components are used, which are originated from an animal or from a human.
The term "sufficient to support the growth of a single cell" means that the culture media are capable of supporting growth of a single cell, but does not require that the media actually be used to support growth of a single cell. The media can be applied for the growth of a single cell or for the growth of a cell population at a concentration of lower than 100 cells/ml or for the growth of a cell population at a cell concentration higher than 100 cells/ml. The media of the present invention is contacted with a population of cells, in growth conditions capable of sustaining clonal growth, that is, growth at very low cell densities, such as densities less then about 100 cells/m1, including single cells.
The term ''cell culture medium", "tissue culture medium", "culture medium", "stock culture medium" "cloning medium" (plural "media" in :A 02756247 2011-09-22 each case) refers to a nutritive solution for cultivating cells or tissues, and may be used interchangeably. A culture medium is a medium which is suitable for cultivation or for incubation of a cell or several cells. Such culture media may contain nutrients for keeping the cell integrity or cell viability or cell growth or cellular productivity. Pre-ferred is a liquid culture medium. A particularly preferred culture me-dium is described in WO 2007/036291 and may be used for the pre-sent invention. A particularly preferred culture medium contains all necessary substances for cell growth, cell viability and cellular pro-. ductivity. A preferred culture medium in particular may contain for example and not being limited to glucose, amino acids, salts, trace elements and fatty acids.
The cell culture of mammalian cells is nowadays a routine operation well-described in scientific textbooks and manuals. It is covered in detail e.g. in R. Ian Fresney, Culture of Animal cells, a manual, 41h edition, Wiley-Liss/N.Y., 2000. Culture media and culture methods, for instance for mammalian cell lines, for use in combination with the culture additives of the present invention are per se well-known in the art. Such culture media are preferably composed of a solvent, such as water, a carbon source, a nitrogen source, amino acids, pH
regulators, trace elements, fatty acids, nucleotides. Preferred culture media for the present invention are standard cell culture media, which may also be adapted to the needs of particular cell types and include, without being restricted to, Roswell Park Memorial Institute (RPMI) 1640 medium, L-15 medium, Dulbecco's modified Eagle's medium (DMEM), Eagle's minimal essential medium (MEM), Ham's F12 medium or lscoves' modified DMEM. Other preferred media are for instance, Ham's F10 or F12 media, which are specially designed for CHO cell culture. Other preferred media for the present invention :A 02756247 2011-09-22 are specially adapted to CHO cell culture and are described for in-stance in EP 0 481 791. A preferred culture medium for the present invention can also be a commercially available medium, for example, but not limited to CD CHO (Gibco, 10743), ProCH05 (BioWhittaker, BE12-766Q), HyQSFM4CHO (HyClone, 8H30548.02).
In a further preferred embodiment of the present invention the cul-ture media can contain L-glutamine, glutamine can be fully or partly replaced with glutamine substitutes, e.g. GLUTAMAX (GIBCO
Cat.Nr: 35050-061). In a further preferred embodiment of the present invention the culture media can contain low concentration of L-glutamine. The concentration of L-glutamine can be maximal 900 mg/I, preferred 600 mg/I, more preferred 300 mg/I, more preferred 100 mg/I, more preferred 50 mg/I, more preferred 20 mg/I. The cul-ture media can be free of L-glutamine. When the culture medium is free of L-glutamine, then it is particularly suitable for application of cells transfected with glutamine synthetase selection gene.
In a further preferred embodiment of the present invention the cul-ture media contain at least one carbohydrate source. Preferred is the application of glucose in a concentration 0-10 g/I. The glucose can be fully or partly substituted with other carbohydrates for example but not limited to fructose, mannose, galactose.
In a further preferred embodiment of the present invention the cul-ture media can be free of any inorganic iron source and/or free of any iron chelating compounds.
Preferred culture media of the present invention may alternatively in one embodiment also contain hydrolysates from animal source, from :A 02756247 2011-09-22 plant source or from yeast. Preferred is a hydrolysate from plant source, e.g. soy bean peptone or yeast hydrolysate.
In a particular preferred embodiment, the culture media of the pre-sent invention are serum-free. In a particular preferred embodiment, the culture media of the present invention are free of products iso-lated directly or indirectly from an animal source. In a particularly pre-ferred embodiment of the present invention, the culture media are animal component free. In a particularly preferred embodiment of the present invention, the culture medium is free of hydrolysates.
In a further preferred embodiment of the present invention the cul-ture media can contain inorganic iron.
In a further preferred embodiment of the present invention the cul-ture media can contain one or more iron chelating compounds.
The term "iron" is meant to identify the transition metal Fe with atomic weight of 55,845. The term iron is the generic term which comprises all molecules containing one or more iron ions for exam-pie Fe3+ and/or Fe2+ ions. The Fe3+ and/or Fe2+ ion can occur in form of an iron salt. Iron salts can be hydrated or dehydrated. In a particu-larly preferred embodiment, the iron source contains Fe (II) and/or Fe (III) ions. In a particularly preferred embodiment, the iron source for use in the present invention is selected from the group consisting of iron (III) phosphate, iron (III) pyrophosphate, iron (III) nitrate, iron (II) sulphate, iron (III) chloride, iron (II) lactate, iron (III) citrate, am-monium iron (III) citrate, iron-dextran and ethylenediaminetetraacetic acid ferric sodium salt or hydrated or dehydrated forms thereof.

:A 02756247 2011-09-22 The iron can also be complexed with another molecule, e.g. with a carrier or with a chelator. Some particularly preferred examples of complexed iron with chelators not being limited to are iron (II) lactate hydrate, iron (Ill) citrate, ammonium iron (Ill) citrate, iron-dextran and ethylenediaminetetraacetic acid ferric sodium salt. The iron may al-ternatively also be complexed with the following additional molecules such as described in US 6,048,728, i.e. pyridoxyl isonicotinoyl hydra-zone, citrate, acetylacetonate, and a variety of other organic acids such as malic acid, succinic acid, fumaric acid, and alpha ketoglu-taric acid. Further iron chelators for use in the present invention are given in WO 2001/016294.
The present invention is not limited to any type of cells. Examples of cell types include mammalian cells, insect cells, bacterial cells, and yeast cells. The cells can also be primary cells or stem cells. The cells may be naturally occurring cells being not transformed or trans-fected. The cells can also be recombinant cells transfected of trans-formed with one or more vectors for recombinant gene expression.
The cells can be transformed with a virus for producing any product, for example viral products. The cells can originate from hamster, mouse, human or any other animal. The cells can also be cell lines, for example but not limited to CHO cells, CHO K1 cells, CHO DUKX
cells, CHO DG44 cells, NSO cells, Per.C6 cells, BHK cells, SP2/0 cells, HEK293 cells.
Further preferred embodiments of the present invention are the sub-ject-matter of the sub-claims.
The following examples and the accompanying figures describe the present invention in more detail.

7,A 02756247 2011-09-22 Figure 1 demonstrates the comparison of the cloning efficiency in conditioned medium and rHSA.
Figure 2 demonstrates comparison of the cloning efficiency using recombinant human serum albumin with and without addition of re-combinant human transferrin.
Figure 3 demonstrates the comparison of the cloning efficiency using rHSA and rHTR separately and in combination.
Figure 4 demonstrates the titration of recombinant human transferrin with and without addition of recombinant human serum albumin and -to the resulting cloning efficiency.
Figure 5 demonstrates the effect of the combined addition of rHSA
and rHTR for promoting cell growth of single cells deposited by FACS. Additionally, these results show the effectiveness of this me-dium formulation for different CHO cell lines.
Examples Cells For all experiments following three CHO cell lines were used:
1) DHFR (dihydrofolate reductase) deficient CHO DG44 host cell line (Urlaub and Chasin, Proc. Natl. Acad. Sc., 1980, 77: 4216).

2) A transfected CHO DG44 sub clone (named clone23) generated from the cell line mentioned in 1) while expressing DHFR and a re-combinant monoclonal antibody. This clone was generated by trans-fection of the CHO DG44 host cell line with a vector carrying the :A 02756247 2011-09-22 gene for DHFR and for an IgG antibody. Transfectants were ampli-fied using MTX in culture medium.

3) CHO K1 host cell line (Puck TT, et al., J. Exp. Med., 1958, 108:
945-956). All applied cells in this invention do not require any protein in culture media for growth and viability. All cell lines grow independ-ently of serum, proteins, growth factors, hydrolysates, albumin and transferrin.
Cell culture conditions Stock culture cells used for single cell cloning were kept in shake flasks or in spinner flasks. Cells were inoculated with a cell concen-tration of 3x105 cells/ml in a shake flask and after growth phase of 2 to 4 days in batch, they reach a cell concentration of 5x105 cells/ml to 100x105 cells/ml. The stock culture was split into fresh culture me-dium every two to four days. This means, a small amount of cell cul-ture was used as inoculum and transferred into a new flask and sup-plemented with fresh culture medium. When cells have not reached high concentration, they were centrifuged during cell split. Cells were cultured at 37 C in a 7.5% CO2 atmosphere in an incubator. Cells were cultured several passages in this way. One passage is defined as culture duration of 2-4 days. Cells for single cell cloning experi-ments were taken from these stock cultures from exponential growth phase.

=

:A 02756247 2011-09-22 Culture media Stock culture medium Two different stock culture media were used during the experiments.
First, a commercially available stock culture medium with unknown recipe (CD CHO, Gibco, 10743) and second a proprietary stock cul-ture medium with following characteristics: The proprietary stock cul-ture medium contains all necessary substances for cell growth, cell viability and cellular productivity, such as but not limited to glucose, amino acids, salts, trace elements and fatty acids. The proprietary 113 stock culture medium is free of serum, proteins, growth factors and peptones. The proprietary stock culture medium is animal compo-nent free. The proprietary stock culture medium contains an inor-ganic iron source for supplying cells with iron. The proprietary stock culture medium does not contain recombinant albumin and does not contain recombinant transferrin. The proprietary stock culture me-dium is supplemented with 6 mM L-glutamine prior to use. The pro-prietary culture medium has an osmolality of 330 mOsmol/kg H20 and a pH of 7.2.
Clonal cell growth was promoted in the cloning medium independent of the applied stock culture medium, demonstrating that the stock culture media recipe do not play a role for clonal cell growth.
Cloning medium Two different cloning medium was applied. First, a commercially available culture medium with unknown recipe (CD CHO, Gibco, 10743) and second a proprietary cloning medium with following :A 02756247 2011-09-22 characteristics: The proprietary cloning medium contains all neces-sary substances for cell growth, cell viability and cellular productivity, such as but not limited to glucose, amino acids, salts, trace elements and fatty acids. The proprietary cloning medium is free of serum, pro-teins, growth factors and peptones. The proprietary cloning medium is animal component free. The proprietary cloning medium contains as inorganic iron source Iron (III) phosphate (Sigma, F1523) at a concentration of 2 mg/I. The proprietary cloning medium does not contain recombinant albumin and does not contain recombinant transferrin. The proprietary cloning medium is supplemented with 2 mM L-glutamine prior to use. The proprietary cloning medium has an osmolality of 290 mOsmol/kg H20 and a pH of 6.9.
Clonal cell growth was promoted in both cloning media demonstrat-ing that the stock culture media recipe do not play a role for clonal cell growth. However, important for clonal cell growth were the inven-tive steps, e.g. supplementation of the cloning media with recombi-nant proteins as described below.
Single cell cloning by limited dilution Limited dilution (LD) was performed by diluting the cell suspension of stock culture from a cell density of higher than 3x105 cells/ml to a cell density of 4 cells/ml (=0.6 cells/150 pl) manually. Cells were diluted in 1:10 steps in cloning medium with a final dilution step of 1:20 in respective supplemented cloning medium. 0.6 cells per well were pipetted in 96-well U-bottom plates (Nunc ) with 150 pl medium per well. The number 0.6 cells/well is the statistical seeding cell density.
In reality, when plates were monitored microscopically after seeding, :A 02756247 2011-09-22 some wells contained no cells and some wells contained 2 or more cells.
Single cell cloning by FACS
Single cell cloning (SCC) by FACS (fluorescent activated cell sorting) was performed by sorting 1 cell per well directly into 96-well U-bottom plates (Nund)). Plates were already provided with 150 pl cloning medium per well. The plates with medium were incubated in incubator prior to cell sorting. FACS sorting was performed in single cell sort mode with a FACSAria (BD Biosciences) equipped with an automated cell deposition unit (ACDU).
Incubation and Evaluation After conducting the SCC, the plates were immediately transferred into the incubator (37 C, 7.5% CO2). The number of successfully expanded clones was evaluated by eye and by microscope 14 days after seeding of single cells. Results are shown as % cloning effi-ciency. 100% cloning efficiency in each experiment was set to the number of colonies grown in parallel running positive controls sup-plemented with 10% FBS (Gibco , heat inactivated). Since cells were not always in identical growth phases when--used for SCC, variations in cloning efficiency occurred between different experiments. This inter-assay variation however, did not distort the overall observations made throughout the study.

:A 02756247 2011-09-22 Example 1: Comparison of conditioned medium and rHSA as culture media additive to promote single cell growth Goal of the experiment was to evaluate whether conditioned medium or recombinant human serum albumin as additive in culture media can promote cell growth when a cell culture is seeded with extremely low cell concentration, e.g. at single cell status.
CHO Clone23 cells were single cell cloned by limited dilution manu-ally as described in material and methods section. For every medium combination two 96 well plates were plated out. Experiment was per-formed as follows:
Positive control (FBS): The cloning medium was supplemented with 10% heat inactivated qualified fetal bovine serum (FBS) from Gibco@
(10100-147). This means 40 ml cloning medium was supplemented with 4 ml FBS (100% stock solution).
Conditioned medium K1: Conditioned medium was prepared from CHO-K1 cultures. CHO-K1 cells were cultured in a shake flask in batch. Conditioned medium was separated from CHO-K1 cells by two centrifugation steps. Initially, cell suspension was centrifuged at 190xg for 3 min at room temperature. Supernatant was then trans-ferred into a new vessel and centrifuged again at 3000xg for 10 min at room temperature. Subsequently, the medium was filtered through a 0.2 pm filter (Acrodisc , PALL). The fresh cloning medium was di-luted with 50% so prepared conditioned medium. This means, 20 ml fresh cloning medium was mixed with 20 ml conditioned medium.

:A 02756247 2011-09-22 Addition of recombinant human serum albumin (rHSA): The cloning medium was supplemented to the final concentration of 2 g/I with recombinant human serum albumin (rHSA) stock solution. This means, 40 ml fresh cloning medium was supplemented with 1.6 ml of a 50 g/I stock solution of rHSA (Sigma , A7223).
The plates were incubated as described in material and methods section and the arising colonies were counted.
Results demonstrate (figure 1) that conditioned medium is not suffi-cient to support clonal growth. The rHSA supports the clonal growth, but the cloning efficacy is not sufficient when compared to the con-trol.
Example 2: Test of recombinant human serum albumin with and without addition of recombinant human transferrin Goal of the experiment was to evaluate whether it is possible to in-crease the cloning efficacy by adding recombinant human transferrin.
CHO Clone23 cells were single cell cloned by limited dilution manu-ally as described in material and methods section. For every media combination two 96 well plates were plated out. Experiment was per-formed as follows:
Positive control (FBS): The cloning medium was supplemented with 10% heat inactivated qualified fetal bovine serum (FBS) from Gibco (10100-147). This means 40 ml cloning medium was supplemented with 4 ml FBS (100% stock solution).

:A 02756247 2011-09-22 Negative control (without supplement): 40 ml pure cloning medium was used without any further supplementation.
Addition of recombinant human serum albumin (rHSA): The fresh cloning medium was supplemented to the final concentration of 2 g/I
with recombinant human serum albumin (rHSA). This means, 40 ml fresh cloning medium was supplemented with 1.6 ml of a 50 g/I stock solution of rHSA (Sigma , A7223).
Addition of recombinant human serum albumin and recombinant human transferrin (rHSA rHTR): The fresh cloning medium was supplemented to the final concentration of 2 g/I with recombinant human serum albumin (rHSA) and further supplemented to the final concentration of 5 mg/I with recombinant human transferrin (rHTR).
This means, 40 ml fresh cloning medium was supplemented with 1.6 ml of a 50 g/I stock solution of rHSA and with 10 pl of a 20 g/I
stock solution of rHTR Millipore (9701-10).
The plates were incubated as described in material and methods section and the arising colonies were counted.
Results demonstrate (figure 2) that without any supplement (negative control) no colonies are visible. When the fresh cloning medium is supplemented with 2 g/I rHSA to the final concentration, around 20%
colonies of the control are growing. Surprisingly, when the cloning medium is supplemented with rHSA and rHTR, the number of grow-ing colonies increases up to 80% of the positive control. It is interest-ing, that the CHO clone 23 cell line used in this experiment was cul-tured in a culture medium without any proteins during stock culture.
The stock culture medium contains an inorganic iron source, and the good growth in stock culture is an evidence of cellular independence 7,A 02756247 2011-09-22 from proteins. The data demonstrate, that in single cell status the cells need rHSA and rHTR for better growth even tough they do not need these recombinant proteins in a cell population. These results demonstrate that the high colony growth might be only due to the addition of rHTR. Hence it was interesting to observe, what impact the exclusive addition of rHTR has without involvement of rHSA (see experiment 3).
Example 3: Evaluating the impact of rHSA and rHTR separately Goal of the experiment was to test the recombinant human serum albumin (rHSA) and recombinant human transferrin (rHTR) sepa-rately and in combination in order to see the effect of each protein separately. Further goal was to evaluate if a synergistic effect of both proteins does exist.
CHO Clone23 cells were single cell cloned by limited dilution manu-ally as described in material and methods section. For every media combination two 96 well plates were plated out. Experiment was per-formed as follows:
Positive control (FBS): The cloning medium was supplemented with 10% heat inactivated qualified fetal bovine serum (FBS) from Gibce (10100-147). This means 40 ml cloning medium was supplemented with 4 ml FBS (100% stock solution).
Addition of recombinant human serum albumin (rHSA): The fresh cloning medium was supplemented to the final concentration of 2 g/I
with rHSA. This means, 40 ml fresh cloning medium was supple-mented with 1.6 ml of a 50 g/I stock solution of rHSA (Sigma*, A7223).

:A 02756247 2011-09-22 Addition of recombinant human transferrin (rHTR): The fresh cloning medium was supplemented with 5 mg/I to final concentration of re-combinant human transferrin (rHTR). This means, 40 ml fresh clon-ing medium was supplemented with 10 pl of a 20 g/I stock solution of rHTR Millipore (9701-10).
Addition of recombinant human serum albumin and recombinant human transferrin (rHSA + rHTR): The fresh cloning medium was supplemented to the final concentration of 2 g/I with recombinant human serum albumin (rHSA) and further supplemented to the final concentration of 5 mg/I with recombinant human transferrin (rHTR).
This means, 40 ml fresh cloning medium was supplemented with 1.6 ml of a 50 g/I stock solution of rHSA and with 10 pl of a 20 g/I
stock solution of rHTR Miflipore (9701-10).
The plates were incubated as described in material and methods section and the arising colonies were counted.
The results demonstrate (figure 3) that rHSA and rHTR have either no improvement or only little improvement of cloning efficacy if they = are applied separately. Surprisingly, when both proteins are com-bined in the same medium, the cloning efficacy increases signifi-cantly up to 90% of the FBS containing medium.
Example 4: Titration of recombinant human transferrin with and without addition of recombinant human serum albumin Goal of the experiment was if the growth promoting effect of both proteins is concentration dependent.

:A 02756247 2011-09-22 Clone23 cells were single cell cloned by limited dilution manually as described in material and methods section. For every media combi-nation two 96 well plates were plated out. Experiment was performed as follows:
Positive control (FBS): The cloning medium was supplemented with 10% heat inactivated qualified fetal bovine serum (FBS) from Gibco (10100-147). This means 40 ml cloning medium was supplemented with 4 ml FBS (100% stock solution).
Addition of recombinant human transferrin (rHTR): The fresh cloning medium was supplemented with increasing concentrations of recom-binant human transferrin (rHTR). Following final concentrations of rHTR have been adjusted by addition of 20 g/I stock solution of rHTR
Millipore (9701-10) into the fresh cloning medium: 5 mg/I, 50 mg/I, 100 mg/I and 200 mg/I.
Addition of recombinant human transferrin and recombinant human serum albumin (rHTR + rHSA): The fresh cloning medium was sup-plemented to the final concentration of 2 g/I with recombinant human serum albumin (rHSA). In all this experiments the concentration of rHSA was kept constant. The rHSA supplemented medium was fur-ther supplemented with varying amounts of recombinant human transferrin (rHTR). Following final concentrations of rHTR have been adjusted by addition of 20 g/1 stock solution of rHTR (Millipore ,9701-10) into the fresh cloning medium:
2 g/I rHSA + 5 mg/I rHTR
2 g/I rHSA + 50 mg/I rHTR

:A 02756247 2011-09-22 2 g/I rHSA + 100 mg/I rHTR
2 g/I rHSA + 200 mg/I rHTR
The plates were incubated as described in material and methods section and the arising colonies were counted.
The results clearly demonstrate (figure 4) the synergistic effect of both proteins. rHTR alone is not capable to promote cell growth. In previous experiments it has been shown, that only rHSA promotes the cell growth approximately up to 20% of the control. The best cell growth promoting effect is visible by combination of both proteins.
Interestingly a very low concentration (5 mg/I) of rHTR is sufficient to achieve cell growth up to 90% of the control cultures.
Example 5: Single cell cloning experiments with different CHO
cell lines by FAGS equipped with automatic cell deposition unit Goal of the experiment was to test the recombinant human serum albumin (rHSA) and recombinant human transferrin (rHTR) in combi-nation with different CHO cell lines. Further goal was to evaluate if this medium formulation successfully expands these cells when they are single cell cloned by FACS and deposited by a robotic unit.
CHO Clone23, CHO K1, and CHO 1JG44 cells were single cell cloned automatically by FAGS as described in material and methods section. For every media combination two 96 well plates were plated.
The experiment was performed as follows:
Positive control (FBS): The cloning medium was supplemented with 10% heat inactivated qualified fetal bovine serum (FBS) from Gibco :A 02756247 2011-09-22 (10100-147). This means 40 ml cloning medium was supplemented with 4 ml FBS (100% stock solution).
Addition of recombinant human serum albumin and recombinant human transferrin (rHSA + rHTR): The fresh cloning medium was supplemented to the final concentration of 2 g/I with recombinant human serum albumin (rHSA) and further supplemented to the final concentration of 5 mg/I with recombinant human transferrin (rHTR).
This means, 40 ml fresh cloning medium was supplemented with 1.6 ml of a 50 g/I stock solution of rHSA and with 10 pl of a 20 g/I
lo stock solution of rHTR Millipore (9701-10).
The plates were incubated as described in material and methods section and the arising colonies were counted.
The results demonstrate the effect of the combined addition of rHSA
and rHTR for promoting cell growth of single cells deposited by FACS (figure 5). Additionally, these results show the effectiveness of this medium formulation for different CHO cell lines. Due to the ro-bust growth of CHO K1 cells, the effects of rHSA and rHTR are not as pronounced when compared with CHO clone23 or CHO DG44 cells. Remarkably, when cells were seeded by FACS, they grow in rHSA and rHTR supplemented medium even better than the cells grown seeded manually by limited dilution.

Claims

CLAIMS:

1. A method for the cultivation of a population of cells in a serum free cell culture medium, wherein the cells of the population of cells are cells which are able to grow in an animal component free medium and wherein the population of cells has a cell concentration of less than 100 cells/ml, comprising the steps of:
(a) culturing a population of cells at a cell concentration greater than 100 cells/ml in a first serum free cell culture medium;
(b) reducing the cell concentration to less than 100 cells/ml;
(c) culturing the cells in a second serum free cell culture medium, wherein the second serum free cell culture medium contains recombinant albumin and recombinant transferrin; and d) culturing the cells in a third serum free cell culture medium which has a lower concentration of recombinant transferrin and/or recombinant albumin than the cell culture medium of step (c).

2. The method according to claim 1, wherein the reducing step in (b) comprises isolating a single cell out of the population of cells.

3. The method according to claim 1 or 2, wherein the cells of the population of cells do not require recombinant transferrin and/or recombinant albumin for growth, when the cells are cultured at a cell concentration greater than 100 cells/ml.

4. The method according to any one of claims 1 to 3, wherein the cells of the population of cells are cells which are adapted to grow in an animal component free medium.

5. The method according to any one of claims 1 to 4, wherein the animal component free medium is a protein free medium.

6. The method according to any one of claims 1 to 5, wherein the cell culture medium used in step (a) contains less recombinant albumin and less recombinant transferrin than the cell culture medium used in step (c).

7. The method according to any one of claims 1 to 6, wherein the cell culture medium used in step (a) and/or in step (c) is an animal component free medium.

8. The method according to any one of claims 1 to 7, wherein the cell culture medium of step (d) is free of recombinant transferrin and recombinant albumin.

9. The method according to any one of claims 1 to 8, wherein the cell culture medium of step (c) has an osmolality between 280 and 320 mOsmol/kg H2O and a pH between 6.8 and 7.1.

10. The method according to any one of claims 1 to 9, wherein the cell culture media used in steps (a) and (c) contain L-glutamine in a concentration lower than 4 mM.

11. The method according to any one of claims 1 to 8, wherein the cell culture media used in steps (a) and (c) contain a non-transferrin bound iron.

12. The method according to any one of claims 1 to 11, wherein the cells are cultured in step (c) for at least 6 days.

13. The method according to any one of claims 1 to 12, wherein the cells are cultured in step (c) for at least 6 days.

14. The method according to any one of claims 1 to 13, wherein in step (c) the culture volume is at most 1 ml.

15. The method according to any one of claims 1 to 14, wherein the cell culture medium used in step (c) contains at least 100 mg/I recombinant albumin and at least 0.5 mg/I recombinant transferrin.

16. The method according to any one of claims 1 to 15, wherein the cell culture medium used in step (c) contains at least 2000 mg/I recombinant albumin and at least 5 mg/I recombinant transferrin.

17. The method according to claim 2, wherein the single cell is isolated by an automatic cell sorting system.

18. The method according to any one of claims 1 to 17, wherein the population of cells is a CHO cell line.